Sun Pharmaceutical Industries (SUNPHARMA) Stock Analyst Review May 2026

This Sun Pharmaceutical Industries analyst review for May 2026 assesses SUNPHARMA at approximately Rs 1,720. Sun Pharmaceutical Industries (NSE: SUNPHARMA) is India’s largest pharmaceutical company and fifth largest specialty generic pharma company globally, with a market capitalisation of Rs 4,13,000 crore. This Sun Pharmaceutical Industries analyst review focuses on the US specialty drug portfolio, global branded generics business, and the specialty dermatology pipeline as the primary value creation drivers.

Click Here – Get Free Investment Predictions

Sun Pharmaceutical Industries Company Snapshot May 2026

This Sun Pharmaceutical Industries analyst review is based on live market data as of May 2026, incorporating the latest quarterly results and analyst consensus targets for Sun Pharmaceutical Industries (NSE: SUNPHARMA), one of India’s largest companies in the Pharmaceuticals sector.

Parameter	Value
NSE Ticker	SUNPHARMA
Sector	Pharmaceuticals
CMP (May 2026)	Rs 1,720
52 Week High	Rs 1,968
52 Week Low	Rs 1,557
Market Cap	Rs 4,13,000 Crore
Trailing P/E	36.50x
Analyst Consensus Target	Rs 2,050
Bull Case Target	Rs 2,300
Bear Case Target	Rs 1,450

Latest Results and Business Performance

Sun Pharma has been delivering consistent double-digit revenue growth driven by the US specialty business, India branded generics, and emerging markets. The US specialty segment including Ilumya (psoriasis), Cequa (dry eye), and the oncology portfolio generates EBITDA margins of 30 to 35 percent. Sun Pharma’s India business grows at 10 to 12 percent YoY through chronic therapy segments (cardiology, neurology, diabetes). This Sun Pharmaceutical Industries analyst review identifies specialty drug NDA filings and US FDA approvals as the key binary catalysts in FY27.

Screen the best stocks on the Univest Screener.

Segment and Business Analysis in This Sun Pharmaceutical Industries Analyst Review

US Specialty Business

The US specialty segment is the highest-margin and fastest-growing division. Ilumya (psoriasis), Cequa (dry eye disease), and oncology drugs drive premium royalty and branded revenues. This segment is the primary stock-level catalyst in this Sun Pharmaceutical Industries analyst review.

India Branded Generics

India contributes approximately 35 percent of consolidated revenue with branded generics across cardiology, neurology, psychiatry, and diabetes. Consistent market share gain at 10 to 12 percent YoY growth is a core strength in this Sun Pharmaceutical Industries analyst review.

Emerging Markets and Rest of World

Sun Pharma has a strong presence in Russia, Romania, and other emerging markets with branded generics offering higher-than-generic margins that support overall revenue mix per this Sun Pharmaceutical Industries analyst review.

Valuation and Analyst Price Targets

At Rs 1,720, SUNPHARMA trades at 36.5x trailing P/E, reflecting the market’s premium for its specialty drug pipeline. The consensus target of Rs 2,050 implies 19 percent upside. This Sun Pharmaceutical Industries analyst review notes that successful US specialty NDA approvals in FY27 could drive further re-rating toward the bull case of Rs 2,300.

Scenario	Target Price
Bull Case	Rs 2,300
Base Case (Consensus)	Rs 2,050
Bear Case	Rs 1,450

Screen the best stocks on the Univest Screener.

Key Catalysts for Sun Pharmaceutical Industries in FY27

Key catalysts in this Sun Pharmaceutical Industries analyst review include new US specialty NDA approvals in dermatology and ophthalmology, Ilumya ARPU expansion as psoriasis market penetration grows, India business maintaining 10 to 12 percent growth, and resolution of any pending US FDA observations clearing the way for additional product launches.

Key Risks in This Sun Pharmaceutical Industries Analyst Review

Key risks in this Sun Pharmaceutical Industries analyst review include US FDA import alerts or Warning Letters at key manufacturing facilities, specialty drug pricing pressure from US payer negotiations and PBMs, generic erosion of key US products, and INR appreciation compressing export revenue in INR terms.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Sun Pharmaceutical Industries Analyst Review Verdict

This Sun Pharmaceutical Industries analyst review concludes that SUNPHARMA at Rs 1,720 is a quality large-cap pharma holding with a best-in-class specialty drug pipeline, dominant India branded generics franchise, and global emerging market presence. The consensus Rs 2,050 target implies 19 percent upside per this Sun Pharmaceutical Industries analyst review. Always consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions on Sun Pharmaceutical Industries Analyst Review 2026

What is the analyst target for Sun Pharma in 2026?

The consensus target is approximately Rs 2,050, with a bull case of Rs 2,300. This Sun Pharmaceutical Industries analyst review notes majority Buy ratings among institutional analysts covering SUNPHARMA.

What is Sun Pharma’s US specialty business?

The US specialty segment includes Ilumya (psoriasis), Cequa (dry eye), and oncology drugs. It is the highest-margin division and the primary stock-level catalyst in this Sun Pharmaceutical Industries analyst review.

Is Sun Pharma a good buy in 2026?

At 36.5x P/E with specialty drug pipeline potential and 19 percent upside to consensus target, this Sun Pharmaceutical Industries analyst review is constructive for pharma investors. Consult a SEBI-registered advisor before investing.

What is Sun Pharma’s India business growth?

India branded generics grow at 10 to 12 percent YoY across chronic therapy segments, contributing approximately 35 percent of consolidated revenue per this Sun Pharmaceutical Industries analyst review.

What are the key US FDA risks?

US FDA import alerts or Warning Letters at manufacturing facilities and specialty drug pricing pressure from PBMs are the primary regulatory risks in this Sun Pharmaceutical Industries analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.